ZYME reports Q2 results tomorrow evening with a split signal: options traders are more cautious than usual, while the analyst community just raised its target for the stock ahead of the print.
The clearest near-term tension is in options positioning. The put/call ratio has climbed to 0.65, roughly 1.7 standard deviations above its 20-day average of 0.46 — the most defensively skewed reading in several weeks. That jump is recent and sharp; through most of July the PCR was running below 0.40, reflecting a more bullish posture. The shift toward puts began around July 28 and has accelerated heading into tomorrow's event. Short interest, by contrast, tells a quieter story: bears have been covering, not building. Short interest has fallen about 9% over the past month to 5.5% of the free float, sitting near a six-week low. Borrow conditions reinforce that picture — the cost to borrow is below 0.5%, and availability is extremely loose at 842%, meaning the lending pool holds roughly eight shares available for every one already borrowed. There is no squeeze dynamic here, and no evidence of a fresh short attack into earnings.
The analyst picture leans constructively bullish, though the stock remains well below where coverage thinks it should trade. HC Wainwright raised its price target this morning — the day before earnings — from $46 to $51, maintaining its Buy rating. That follows a string of upward revisions: Truist lifted its target in early July, and Wells Fargo nudged theirs higher in late June. The mean price target across coverage sits at $39.75, roughly 74% above the current price of $22.79. The bull case centres on zanidatamab, Zymeworks' HER2-targeted bispecific antibody, where Phase 3 trial data showed statistically significant improvements in progression-free survival for first-line HER2+ gastroesophageal cancer. The bear case is a standard clinical-stage reality check: binary regulatory risk, ongoing cash burn, and dilution risk over time. The EPS surprise factor score ranks in the 97th percentile — the company has consistently beaten estimates — but the 90-day EPS momentum score sits at just 28, suggesting near-term estimate revisions have drifted lower.
One ownership detail worth noting: EcoR1 Capital holds 32% of the company's shares, an unusually concentrated anchor position for a stock of this size. Rubric Capital Management added 1.25 million shares in Q1, bringing its stake to 9.8%. Perceptive Advisors initiated a position of almost 4 million shares, as reported in April. That cluster of specialist healthcare investors holding large chunks of the float likely reduces the short-term float available for trading — which may partly explain why borrow availability looks so ample relative to actual short interest.
The earnings history for ZYME points to material post-print moves. The most recent Q1 report in May produced a 13.5% single-day decline and a roughly equivalent loss over the following five days. That was a hard miss on market expectations, and the stock has shed about 13% over the past month from that starting point. The options market, with its elevated PCR, appears to be pricing in a similarly sized move — though in which direction remains the question that tomorrow's report will answer.
The binary to watch is less about revenue line items and more about any FDA-related commentary on zanidatamab's review timeline, given that a regulatory decision on the gastroesophageal cancer indication is the single catalyst most analysts tie their targets to.
See the live data behind this article on ORTEX.
Open ZYME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
